Genomic mapping and survival prediction in GBM: Molecular sub-classification as an adjunct to hemodynamic imaging biomarkers - A TCGA Glioma Phenotype.

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.
DIAGNOSTIC ROLE OF STATIC AND DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING IN THE EVALUATION OF SOFT TISSUE TUMOURS Abstract No. IRIA
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
Mungunkhuyag Majigsuren1, Takashi Abe1, Masafumi Harada1
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
Julio Arevalo Perez 1, Kyung K. Peck 2, Robert J. Young 1, Andrei I Holodny 1, Sasan Karimi 1 John K. Lyo 1 1 Department of Radiology 2 Department of Medical.
Imaging of bevacizumab treated brain: traditional and emerging concepts Asim K. Bag Joel K Cure Aparna Singhal David Wever Asim K. Bag Joel K Cure Aparna.
Atypical and aggressive meningiomas: Is there a role for radiologists in guiding treatment? #EP-53 Anthony Galinato MD, Feras Mossa-Basha MD, Ishani Dalal.
Clinical Trials, TCGA: Deep Integrative Research RT, Imaging, Pathology, “omics” Joel Saltz MD, PhD Director Center for Comprehensive Informatics.
Estimating cancer survival and clinical outcome based on genetic tumor progression scores Jörg Rahnenführer 1,*, Niko Beerenwinkel 1,, Wolfgang A. Schulz.
Imaging Genomics: Correlation of Invasive Genomic Composition and Patient Survival Using Qualitative and Quantitative MR Imaging Parameters RR Colen 1,
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Radiogenomics in glioblastoma multiforme
THE CORRELATIONS OF 3D PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING AND DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION MRI IN BRAIN TUMORS Delgerdalai Khashbat,
QUANTITATIVE MRI OF GLIOBLASTOMA RESPONSE Bruce Rosen, MD, PhD Athinoula A. Martinos Center for Biomedical Imaging, MGH. Future Plans/Upcoming Trials Reproducibility.
LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:
Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.
Department of Radiology and Imaging Sciences Division of Neuroradiology University School of Medicine.
ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.
Objective Selection of GBM Imaging Features for Clinical Trials Bradley Erickson, Daniel Blezek, Panos Korfiatis, Jian Su, Ross Mitchell Background: We.
Prediction of Glioblastoma Multiforme Patient Time to Recurrence Using MR Image Features and Gene Expression Nicolasjilwan, M.1·Clifford, R.2·Flanders,
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
© NlH National Center for Image Guided Therapy, 2012 ASNR 2012 Imaging Genomic mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme.
Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.
ASNR 2012 Methodology for Imaging Genomics of Gliomas
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Irradiation of stem cell niches in the periventricular and sub granular zones in gbm : A Prospective study Akram K S, Monica I, Deepa J, Kesava R, Fayaz.
Correlation and fusion of perfusion and spectroscopic MR imaging for the characterisation of brain tumors A. Förschler 1), K. Vester 1), G. Peters 2),
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
IsotropicAnisotropic ROLE OF DIFFUSION TENSOR IMAGING (DTI) IN INTRACRANIAL MASSES Abstract Number: 117.
Prediction of Glioblastoma Multiforme Patient Survival Using MR Image Features and Gene Expression Control/Tracking Number: 11-O-1519-ASNR Nicolasjilwan,
Correlation of Leptomeningeal Disease on MRI Between the Brain and Spine in Patients Presenting to a Tertiary Referral Center Poster #: EP-47 Control #:
ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.
University of Michigan Department of Radiology Role of MR Spectroscopy in Differentiating Radiation Necrosis from Tumor Recurrence. Effects of radiation.
Azienda Ospedaliero-Universitaria, Arcispedale S. Anna,
SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
XXV^ Riunione Nazionale MITO Innovation in gynecologic cancer: optimal therapy, quality of life, precision medicine. Naples, June Targeting.
Radiology 2012; 265:780–789 Departments of Radiology Kanazawa University Graduate School of Medical Science Azusa Kitao, MD et al. R3 Kwon Young Ho.
The Contribution of caBIG and In Silico Resources to Glioblastoma Research Daniel J. Brat MD, PhD Department of Pathology and Laboratory Medicine Emory.
Tumor Heterogeneity: From biological concepts to computational methods Bo Li, PhD Dana Farber Cancer Institute Harvard Statistics Department.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
S. CONDETTE-AULIAC 1, A. BOULIN 1, O. COSKUN 1, L. BOZEC-LE MOAL 2, S. ALDEA 3, S.GUIEU 1, G. RODESCH 1. 1 Neuroradiology department, 2 Oncology department,
INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.
PD: Joel Saltz, MD, PhD PI: Daniel J. Brat MD, PhD Emory University School of Medicine In Silico Center for Brain Tumor Research.
Intratumoral topography of CNS gliomas revealed by diffusion tensor imaging: correlations with tumor volume and grade A. Jakab 1, P. Molnár 2, M. Emri.
ASNR 54rd Annual Meeting ASNR 54rd Annual Meeting
Differentiation between Primary Central Nervous System Lymphoma and Glioblastoma on 3T-MR Imaging: Multivariate Analysis M. Kitajima 1, T. Hirai 1, Y.
Metabolic Syndrome and Progression of Mild Cognitive Impairment
miRNA-targets cross-talks: key players in glioblastoma multiforme
Correlation of tumor blood volume and apparent diffusion coefficient values with the prognostic parameters of head and neck squamous cell carcinoma Abdel.
Spectroscopy Voxel-wise
MR images analysis of glioma
MR Perfusion and Diffusion Values in Gliomas
Ali Batouli1 Dennis Monks1 Sobia Mirza1 Michael Goldberg1
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Volume 17, Issue 1, Pages (January 2010)
Volume 4, Issue 3, Pages (August 2013)
Coiffier B et al. Proc ASH 2011;Abstract 265.
Bar graph of ADC values (s/mm2) for tumor, contralateral normal tissue, ipsilateral normal tissue, and edema for the group of 15 patients with high-grade.
Presentation transcript:

Genomic mapping and survival prediction in GBM: Molecular sub-classification as an adjunct to hemodynamic imaging biomarkers - A TCGA Glioma Phenotype Research Group Project Rajan Jain, MD Division of Neuroradiology, Department of Radiology Department of Neurosurgery Henry Ford Health System Assistant Professor, WSU School of Medicine Detroit, MI, US 34a- 34a - Adult Brain Neoplasms III Tuesday, April 24, O-876-ASNR12-O-876-ASNR

TCGA Glioma Phenotype Research Group Rajan Jain, 1,2 Laila Poisson, 3 Jayant Narang, 1 David Gutman, 4 Adam Flanders, 5 Lisa Scarpace, 2 Scott N Hwang, 4 Chad Holder, 4 Max Wintermark, 6 Rivka R Colen, 7 Justin Kirby, 8 John Freymann, 8 Brat Daniel, 4 Carl Jaffe, 9 Tom Mikkelsen 2 1 Division of Neuroradiology, Department of Radiology, 2 Department of Neurosurgery and 3 Department of Public Health Sciences, Henry Ford Health System, Detroit, MI 4 Emory University, Atlanta, GA; 5 Thomas Jefferson University Hospital, Philadelphia, PA; 6 University of Virginia, Charlottesville, VA; 7 Brigham & Womens Hospital, Boston, MA; 8 SAIC-Frederick, Inc.; 9 Boston University, Boston, MA

Disclosures  Funded by NCI Contract No. HHSN E.

 Recently, there has been progress in understanding the molecular basis of the tumor aggressiveness and heterogeneity.  Various molecular sub-classifications have been proposed based on the genetic makeup of GBM with the hope that a better understanding of origin of tumor cells and molecular pathogenesis may predict response to targeted therapies.  Phillips HS, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):  Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, VEGFR, and NF1. Cancer Cell 2010;17(1): . Background : Genomic Mapping

Phillips HS, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3): High-Grade Gliomas: Molecular Sub-classes

 Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, VEGFR, and NF1. Cancer Cell 2010;17(1): GBM: Molecular Sub-classes

 The Cancer Genome Atlas (TCGA) researchers have recently cataloged recurrent genomic abnormalities in GBM providing a platform for better understanding of the molecular basis of these aggressive but heterogeneous tumors.  In parallel the Cancer Imaging Program is retrospectively obtaining radiological imaging data for TCGA patients and making it available via The Cancer Imaging Archive (TCIA).  TCIA is a large and growing archive service providing DICOM images for use in research  TCGA-GBM collection currently includes over 170 de- identified glioblastoma subjects with accrual still ongoing TCGA and TCIA

Radio-genomics Integration of this vast genomic information with imaging data (radio- genomics) May provide an opportunity to use some of the non-invasive imaging features or parameters as biomarkers.

 A limited number of publications on this topic have correlated morphologic imaging features (presence or absence of contrast enhancement) with various gene expression pathways affecting tumor cell mitosis, migration, angiogenesis, hypoxia, edema and apoptosis. Radio-genomics: Morphologic Features Proc Natl Acad Sci U S A 2008;105(13): Diagn Mol Pathol 2006;15(4): Radiology 2008;249(1):

 Barajas et al correlated histologic features with ADC and rCBV estimates, but the authors did not directly correlate physiologic measures with gene expression. Radiology 2010;254(2):  Pope et al correlated ADC histogram analysis with differential gene expression. AJNR published online  Jain et al correlated perfusion parameters (tumor blood volume and permeability) with angiogenesis related gene expression in GBM. AJNR published online Radio-genomics: Functional Imaging Markers

Purpose  The purpose of this study was to correlate tumor blood volume, measured using DSC T2* magnetic resonance (MR) perfusion with patient survival and also correlate it with molecular sub-classes of GBM.

Material and Methods: Patient Population 57 patients with treatment naïve GBM underwent DSC T2* MR perfusion studies at 2 different institutions and were selected from TCIA’s TCGA-GBM collection. 50 patients had gene expression data available from TCGA. 35 patients at Institute 1 HFH 3.0 T scanner, n= T scanner, n=21 15 patients at Institute 2 UCSF 1.5 T scanner, n=15 According to those TCGA requirements, the pathology was confirmed as GBM using adequate frozen tissue ≥ 0.5 g consisting of ≥70% tumor nuclei and < 50% necrosis.

Material and Methods: MRI Image acquisition Institute 1Institute mmol/kg Gd-DTPA, 5ml/sec 95 phases of GE T2*60 phases of GE T2* TR = 1900 msec, TE =40 msec, and flip angle =90° TR = 2000 msec, TE =54 msec, and flip angle =30° Temporal resolution 2.0 sec Matrix size128 x 128, 26-cm FOV Slice thickness 5 mmSlice thickness 3-6 mm

Material and Methods: MRP Post-processing Studies from both institutions were processed using NordicICE software (NordicImagingLab AS) using the FDA approved DSCT2* perfusion module. The module corrects for contrast agent leakage from the intravascular to extracellular space using the method published by Boxerman et al AJNR Am J Neuroradiol 2006;27(4): Normalized relative cerebral blood volume (rCBV) maps with leakage correction were produced by the software, which normalizes the CBV relative to a globally determined mean value.

Material and Methods: Image Analysis ROIs were drawn on the rCBV maps fused with post-contrast T1W images and FLAIR images. rCBV mean the contrast enhancing portion of the tumor (excluding any areas of necrosis and vessels) rCBV max 10 x 10 voxel ROI was placed on the hottest appearing part of the tumor rCBV NEL 3, 10 x 10 voxel ROIs on non-enhancing FLAIR abnormality within 1 cm of the edge of the enhancing lesion

 Comparison of average rCBV measures between groups was done using two-sample t-tests or one-way ANOVA.  Kaplan-Meier estimation was used to calculate median survival and for some univariate testing.  Survival analysis with Cox proportional hazards models was employed primarily to estimate hazard ratios and for testing multivariable models. Material and Methods: Statistical Analysis

 Potential covariates in the multivariable models –Patient age at diagnosis (years, continuous), –MR scanner type (1.5T, 3T) –molecular classification (Verhaak or Phillips) Huse J et al. Glia 2011;59(8): –Karnofsky performance score (KPS, continuous) –level of resection (gross-total, sub-total)  Age and scanner were not significant predictors and did not enhance the models so they were excluded from the presented models for the sake of parsimony given the sample size.  KPS and resection data were only available for samples from institution 1. Material and Methods: Statistical Analysis

Results: rCBV analysis using molecular sub-classification rCBV mean rCBV max rCBV NEL Verhaakp=0.66p=0.95p=0.43 Classical (n=10)2.66 (0.78)4.55 (0.76)0.66 (0.24) Mesenchymal (n=17)2.61 (1.26)4.80 (1.49)0.88 (0.45) Neural (n=11)2.30 (0.84)4.68 (0.95)0.81 (0.27) Proneural (n=12)2.27 (0.68)5.06 (3.61)0.84 (0.26) Phillipsp=0.32p=0.57p=0.70 Mesenchymal (n=24)2.68 (1.16)4.76 (1.33)0.83 (0.40) Proneural (n=20)2.32 (0.72)5.03 (2.79)0.83 (0.25) Proliferative (n=6)2.15 (0.59)4.04 (0.65)0.70 (0.30)

Results: Survival analysis using Verhaak sub-classification Median overall survival (OS) was 1.14 years (IQR: 0.49, 2.11). When the Verhaak classification scheme was applied to these samples, the classical sub-class had the best survival, with median of 2.13 years (IQR: 1.53, 2.59) and the proneural sub-class had the worst survival with median 0.41 years (IQR: 0.65, 1.19). Verhaak et al Cancer Cell 2010;17(1): Present study

Results: Survival analysis using Verhaak sub-classification  The difference in survival by Verhaak sub-classification was significant between groups with the difference being more prominent earlier during follow-up (Wilcoxon P=0.0445, log-rank P=0.0696).  However, the proneural subclass also had the worst median survival (0.94 years, IQR: 0.78, 1.23) in the publication by Verhaak et al. Verhaak et al Cancer Cell 2010;17(1): Present study

Results: Survival analysis using Phillips sub-classification There was no evidence that the Phillips classification was associated with survival in our sample (log-rank P=0.6432, Wilcoxon P=0.4548). The best median survival is attributed to the mesenchymal sub-class with 1.28 years (IQR: 0.61, 2.22), followed closely by the proneural subclass with 1.12 years (IQR: 0.33, 1.86). Phillips et al Cancer Cell 2006;9(3): Present study

Results: Survival analysis using Phillips sub-classification The proliferative sub-class had the worst median survival at only 0.54 years (IQR: 0.34, 3.96) but this class was only represented by six patients (five deaths), one of whom was still surviving at 3.96 years Phillips et al Cancer Cell 2006;9(3): Present study

Results: Survival analysis using only rCBV measures ParametersMeanMaxNEL Model 1:rCBV1.25 (0.1918)1.24 (0.0131)2.45 (0.0555) Model 2:rCBV (0.0212)1.24 (0.0062)2.56 (0.0704) Verhaak(0.0250)(0.0476)(0.0917) Classical Mesenchymal Neural Proneural1.00 Model 3:rCBV (0.1670)1.24 (0.0152)2.51 (0.0566) Phillips(0.5892)(0.6888)(0.6533) Mesenchymal Proliferative Proneural1.00

Results: Survival analysis using rCBV and molecular sub-classification ParametersMeanMaxNEL Model 1:rCBV 1.25 (0.1918) 1.24 (0.0131)2.45 (0.0555) Model 2:rCBV (0.0212) 1.24 (0.0062)2.56 (0.0704) Verhaak (0.0250)(0.0476)(0.0917) Classical Mesenchymal Neural Proneural1.00 Model 3:rCBV (0.1670)1.24 (0.0152)2.51 (0.0566) Phillips(0.5892)(0.6888)(0.6533) Mesenchymal Proliferative Proneural1.00

Results: Survival analysis using rCBV and molecular sub-classification ParametersMeanMaxNEL Model 1:rCBV1.25 (0.1918)1.24 (0.0131)2.45 (0.0555) Model 2:rCBV (0.0212)1.24 (0.0062)2.56 (0.0704) Verhaak(0.0250)(0.0476)(0.0917) Classical Mesenchymal Neural Proneural1.00 Model 3:rCBV (0.1670)1.24 (0.0152)2.51 (0.0566) Phillips (0.5892)(0.6888)(0.6533) Mesenchymal Proliferative Proneural1.00

 Hemodynamic tumor measures (rCBV) using MR perfusion did not have any significant correlation with the various sub- classes using the two most commonly accepted molecular sub-classification systems of GBM.  But rCBV measures did provide important prognostic information, as patients in whom the tumor had higher rCBV showed worse prognosis and poor survival. Conclusions

 Verhaak sub-classification schema remained significant in the survival models providing additional survival information about rCBV mean measurements.  Molecular mapping of GBM can provide important therapy targets by providing insight into the molecular basis for tumor cell origin; however, in vivo imaging markers (such as rCBV measures) can provide important prognostic information that may be used as an adjunct to genomic markers in future. Conclusions